Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

• Published in: Leukemia & lymphoma Vol. 57; no. 1; pp. 86 - 91
• Main Authors: Kelleher, Nicholas, Gallardo, David, González-Campos, José, Hernández-Rivas, Jesús M., Montesinos, Pau, Sarrá, Josep, Gil, Cristina, Barba, Pere, Guàrdia, Ramon, Brunet, Salut, Bernal, Teresa, Martínez, Maria-Pilar, Abella, Eugènia, Bermúdez, Arantxa, Sánchez-Delgado, Magdalena, Antònia, Cladera, Gayoso, Jorge, Calbacho, María, Ribera, Josep-Maria
• Format: Journal Article
• Language: English
• Published: United States 02.01.2016
• Subjects: Adolescent; Adult; Aged; Biomarkers; Chromosome Aberrations; Female; Hematologic Neoplasms - epidemiology; Humans; Incidence; Male; Middle Aged; Neoplasms - epidemiology; Neoplasms, Second Primary - diagnosis; Neoplasms, Second Primary - epidemiology; Neoplasms, Second Primary - genetics; Neoplasms, Second Primary - mortality; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Prognosis; Recurrence; Young Adult; secondary; Acute lymphoblastic leukemia; cytogenetics; prognosis
• ISSN: 1042-8194; 1029-2403; 1026-8022; 1029-2403
• DOI: 10.3109/10428194.2015.1040013

Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized. We analyzed the characteristics and outcome of patients with s-ALL and compared them with those of patients with de novo- ALL. Of 448 patients, 24 (5%) had previous neoplasia. Sixteen patients had received previous cytotoxic therapy (therapy-associated ALL, t-ALL), and eight had not (antecedent-malignancy ALL, am-ALL). Except for more advanced age in patients with s-ALL, no statistically significant differences were observed in WBC count, CNS involvement, immunophenotype or cytogenetics between the groups, nor in complete remission (t-ALL: 94%; am-ALL: 75%; de novo-ALL: 85%), 3-year remission duration (58%; 50%; 72%), overall survival (71%; 38%; 60%) or event-free survival (53%, 38%; 53%). Our study did not show poor clinical or cytogenetic features or inferior outcome in ALL patients with antecedent neoplastic disease, irrespective of the type of treatment received for the neoplasia.